Association of MTHFR, GSTP1, ERCC1 polymorphisms and response to FOLFOX in colorectal cancer patients

Abstract

Abstract: AIM: To investigate the relationship between the polymorphisms of MTHFR, GSTP1,ERCC1 and the response to FOLFOX chemotherapy in advanced colorectal cancer. METHODS: A total of 150 patients diagnosed as an advanced colorectal cancer by the pathology were treated with FOLFOX chemotherapy and DNA of peripheral blood-leukocytes was obtained before the treatment, MTHFR,GSTP1,ERCC1 genetype were detected by the HRM-SNP method. RESULTS: (1)The frequencies of MTHFR429 Glu/Glu, Glu/Ala, Ala/Ala were 59.1%, 37.0%, 3.9%; MTHFR 222 Ala/Ala, Ala/Val, Val/Val were 12.6%,47.2%,40.1%;GSTP1-105 Ile/Ile, Ile/Val,Val/Val genetypes were 63.0%,33.1%,3.9%;ERCC1-118AA, AT,TT genetypes were 50.4%, 41.7%,7.9%,respectively.(2)The effective rate of FOLFOX chemotherapy among patients with GSTP1-105 Ile/Ile,Ile/Val+Val/Val genetypes were 19.7%,20.5%,OR=2.876,95%CI(1.288,6.424),P<0.05;MTHFR 222 Ala/Ala, Ala/Val+Val/Val genetypes were 11.8%,28.3%,OR=2.236, 95%CI(1.020,5.017),P<0.05,respectively,which was a significant difference. CONCLUSION: The polymorphisms of MTHFR,GSTP1,ERCC1 correlates with the clinical response to FOLFOX chemotherapy and the genetype detected by the HRM-SNP method may be a predictor of sensitivity to FOLFOX chemotherapy.

Key words: colorectal cancer, MTHFR,GSTP1,ERCC1, gene polymorphism, FOLFOX, response

CLC Number:

R969

SHEN Dong-ya, XIE Hai-tang, CHEN Yao, XIAO Jian, ZHANG Wei, ZHANG Xue, ZHOU Hong-hao. Association of MTHFR, GSTP1, ERCC1 polymorphisms and response to FOLFOX in colorectal cancer patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 75-81.

References

[1] Cortejoso L, García MI, García-Alfonso P,et al. Differential toxicity biomarkers for irinotecan- and oxaliplatin containing chemotherapy in colorectal cancer [J].Cancer Chemother Pharmacol, 2013,71(6):1463-1472.
[2] Kelly H, Goldberg RM.Systemic therapy for metastatic colorectal cancer: current options, current evidence[J]. Clin Oncol,2005,23(20):4553-4560.
[3] Raymond E, Faivre S, Woynarowski JM,et al.Oxaliplatin: mechanism of action and antineoplastic activity[J].Semin Oncol,1998,25(2 Suppl 5):4-12.
[4] Iyer L, Ratain MJ.Clinical pharmacology of camptothecins[J].Cancer Chemother Pharmacol,1998,42(Suppl):S31-S43.
[5] Evans WE, Relling MV.Pharmacogenomics: translating functional genomics into rational therapeutics[J]. Science,1999,286: 487-491.
[6] de Gramont A, Figer A, Seymour M,et al.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J]. Clin Oncol,2000,18 (16): 2938-2947.
[7] Oki E, Emi Y, Akagi Y, et al.Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701)[J]. Oncology,2013,84(4):233-239.
[8] Eisenhauer EA, Therasse P, Bogaerts J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[9] Kumamoto K, Ishibashi K, Okada N, et al.Polymorphisms of GSTP1, ERCC2 and TS_3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients[J]. Oncol Lett, 2013,6(3):648-654.
[10] Peklak-Scott C, Smitherman PK, Townsend AJ, et al. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin[J]. Mol Cancer Ther,2008,7(10):3247-3255.
[11] Moscow JA, Fairchild CR, Madden MJ, et al.Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors[J]. Cancer Res,1989, 49(6): 142-148.
[12] Ban N, Takahashi Y, Takayama T, et al.Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan and etoposide[J]. Cancer Res,1996, 56(15): 3577-3582.
[13] Watson MA, Stewart RK, Smith GB, et al.Human gluta-thione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution[J]. Carcinogenesis,1998,19(2): 275-280.
[14] Stoehlmacher J, Park DJ, Zhang W, et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer[J]. Br J Cancer,2004,91(2): 344-354.
[15] Chen YC, Tzeng CH, Chen PM, et al.Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX4 treatment in Asian patients with colorectal carcinoma[J].Cancer Sci, 2010,101(2): 530-535.
[16] Watson MA, Stewart RK, Smith GB, et al.Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution[J].Carcinogenesis, 1998,19(2): 275-280.
[17] Martin LP, Hamilton TC, Schilder RJ.Platinum resistance: the role of DNA repair pathways[J].Clin Cancer Res,2008,14(5):1291-1295.
[18] Shirota Y, Stoehlmacher J, Brabender J, et al.ERCC1 and thymidylatesynthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy[J]. Clin Oncol, 2001,19(23):4298-4304.
[19] Yin M, Yan J, Martinez-Balibrea E,et al.ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis[J].Clin Cancer Res, 2011,17(6):1632-1640.
[20] Rustum YM, Trave F, Zakrzewski SF, et al.Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin[J]. NCI Monogr,1987, 5: 165-170.
[21] Chéradame S, Etienne MC, Formento P, et al.Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients[J].ClinOncol,1997,15(7):2604-2610.
[22] Rozen R.Molecular genetics of methylenetetrahydrofolate reductase deficiency[J].Inherti Metab Dis, 1996,19(5): 589-594.
[23] Weisberg I, Tran P, Christensen B,et al.A second genetic polymorphism in methylenetetra-hydrofolate reductase (MTHFR) associated with decreased enzyme activity[J]. Mol Genet Metab, 1998,64(3): 169-172.
[24] DeVos L, Chanson A, Liu Z, et al. Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folates, homocysteine, and DNA uracil concentrations[J].Am J Clin Nut,2008, 88(4): 1149-1158.
[25] Cohen V, Panet-Raymond V, Sabbaghian N, et al.Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy[J].Clin Cancer Res,2003,9(5): 1611-1615.
[26] Marcuello E, Altes A,Menoyo A, et al.Methylenetetrahydrofolate reductase gene polymorphis ms:genomic predictors of clinical response to fluoropyrimidine-based chemotherapy[J] ? Cancer Chemother Pharmacol,2006, 57(6): 835-840.
[27] Suh KW, Kim JH, Kim Y, et al, Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene[J] ? Ann Surg Oncol,2006,13(11): 1379-1385.
[28] Ruzzo A, Graziano F, Loupakis F,et al.Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy[J].J Clin Oncol,2007,25(10):1247-1254.
[29] Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F,et al.Methylenetetrahydrofolatereductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients Marie-Christine[J].Br J Clin Pharmacol, 2010,69(1):58-66.